Palvella Therapeutics (PVLA) said the US Patent and Trademark Office granted it a patent for claims related to the company's Qtorin 3.9% rapamycin anhydrous gel candidate.
The patent provides broad protection through 2038 for anhydrous topical composition and methods of use for the potential microcystic lymphatic malformations treatment, the company said.
The drug has already been granted US and Food Drug Administration breakthrough therapy, orphan drug and fast track designations, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.